| Inhibition of RIPK2 relative to control - BioAssay Summary Imidazo[1,5-a]quinoxalines were synthesized that function as irreversible Bruton's tyrosine kinase (BTK) inhibitors. The syntheses and SAR of this series of compounds are presented as well as the X-ray crystal structure of the lead compound 36 in complex with a gate-keeper variant of ITK enzyme. The lead compound showed good in vivo efficacy in preclinical RA models. ..more |
_ | |
||||||||||||||||||||||||||||||||||||||||||||||||
Tested Compound: Description: Title: Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis. Abstract: Imidazo[1,5-a]quinoxalines were synthesized that function as irreversible Bruton's tyrosine kinase (BTK) inhibitors. The syntheses and SAR of this series of compounds are presented as well as the X-ray crystal structure of the lead compound 36 in complex with a gate-keeper variant of ITK enzyme. The lead compound showed good in vivo efficacy in preclinical RA models. (PMID: 21958547) Comment Putative Target: ChEMBL Target ID: 20025 Target Type: SINGLE PROTEIN Pref Name: Serine/threonine-protein kinase RIPK2 Description: Receptor-interacting serine/threonine-protein kinase 2 Organism: Homo sapiens Tax ID: 9606 Confidence: Homologous single protein target assigned Relationship Type: Homologous protein target assigned ChEMBL target type: Target is a single protein chain Categorized Comment ChEMBL Assay Type: Binding ChEMBL Assay Data Source: Scientific Literature Result Definitions
Data Table (Concise)
PageFrom: |
||||||||||||||||||||||||||||||||||||||||||||||||||